586 studies found for:    Open Studies | "Ovarian Diseases"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Ovarian Diseases"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Value of MRI in the Characterization of Ovarian Masses Unable to Classify With Ultrasound Using the International Ovarian Tumor Analysis (IOTA) Simple Rules
Condition: Patients With a Sonographically Unclassifiable Adnexal Mass Using the IOTA Simple Rules
Intervention: Other: Diffusion/Perfusion-weighted Magnetic Resonance Imaging
2 Recruiting Mediterranean Diet Versus Hypocaloric Diet in PCOS
Condition: Polycystic Ovary Syndrome
Interventions: Other: mediterranean diet, restricted calorie;   Other: hypocaloric diet, restricted calorie
3 Recruiting Mediterranean Diet as Treatment for Normal Weight Women With PCOS
Condition: Polycystic Ovary Syndrome
Interventions: Other: mediterranean diet;   Other: normocaloric diet
4 Recruiting Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
5 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
6 Recruiting Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Conditions: Renal Cell Carcinoma;   Colorectal Adenocarcinoma;   Non-squamous Non-small Cell Lung Cancer;   Platinum-refractory Ovarian Carcinoma;   Cervical Carcinoma
Interventions: Drug: Nintedanib;   Drug: Bevacizumab
7 Recruiting PerClot Compared to Usual Care in Gynaecology Procedures
Conditions: Endometriosis;   Ovarian Cyst;   Menorrhagia;   Cancer;   Uterine Fibroids
Interventions: Device: PerClot;   Device: Floseal, Surgicel, Surgiflo, Arista;   Procedure: Electrocautery/Diatermy
8 Not yet recruiting Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
Conditions: Fallopian Tube Carcinoma;   Peritoneal Carcinoma;   Epithelial Ovarian Cancer
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin
9 Recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
10 Not yet recruiting Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant NY-ESO-1 Protein;   Drug: Sirolimus
11 Recruiting Point of Care 3D Ultrasound for Various Applications: A Pilot Study
Conditions: Appendicitis;   Evidence of Cholecystectomy;   Gallstones;   Pregnancy, Ectopic;   Aortic Aneurysm;   Kidney Stones;   Intrauterine Pregnancy;   Diverticulitis;   Abdominal Injuries;   Tumors;   Pancreatitis;   Digestive System Diseases;   Gastrointestinal Diseases;   Intraabdominal Infections;   Intestinal Diseases;   Pregnancy;   Vascular Disease;   Uterine Fibroids;   Ovarian Cysts;   Uterine Abnominalies;   Bladder Abnominalies;   Testicular Abnominalies;   Polyps
Intervention:
12 Not yet recruiting Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: PDS;   Drug: 6 cycles of standard chemotherapy;   Drug: 3 cycles of standard NACT;   Procedure: IDS;   Drug: 3 cycles of standard chemotherapy
13 Recruiting Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Condition: Relapsed Ovarian Cancer
Intervention: Drug: trabectedin
14 Recruiting Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
Condition: Infertility
Intervention: Drug: Cetrorelix
15 Not yet recruiting Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
Condition: Ovarian Epithelial Cancer
Interventions: Drug: Olaparib;   Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
16 Not yet recruiting Study of Azacitidine and Durvalumab in Advanced Solid Tumors
Conditions: Microsatellite Stable Colorectal Carcinoma;   Platinum Resistant Epithelial Ovarian Cancer Type II;   Estrogen Receptor Positive and HER2 Negative Breast Cancer
Interventions: Drug: Azacitidine;   Drug: Durvalumab
17 Not yet recruiting Improving Quality of Care for Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Neoplasms;   Quality of Life
Intervention: Other: Questionnaires
18 Recruiting KOrean Borderline Ovarian Tumor (KOBOT) Registry
Condition: Ovarian Neoplasms
Intervention:
19 Recruiting Is There Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?
Conditions: Polycystic Ovary Syndrome;   Insulin Resistance;   Vitamin D Deficiency
Intervention:
20 Not yet recruiting Combined Letrozole and Clomid in Women With Infertility and PCOS
Conditions: Polycystic Ovary Syndrome;   Infertility
Interventions: Drug: Clomiphene;   Drug: Letrozole

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years